Literature DB >> 18507068

NOTES--A new era?

Jörg Zehetner1, Wolfgang U Wayand.   

Abstract

BACKGROUND/AIMS: After the first reports from the United States and India of accessing the peritoneal cavity via a transgastric route and performing operations without any abdominal incision, surgeons, as well as gastroenterologists worldwide, became interested in developing research projects in this topic. We evaluated the first papers and reports about the research and new techniques to focus on the possible advantages of NOTES (Natural Orifice Translumenal Endoscopic Surgery).
METHODOLOGY: The literature was screened in the time period January 2000 to June 2007 for research and development in NOTES and several reports and abstracts from the year 2007 (January to June) were reviewed.
RESULTS: Several research groups in the U.S. and Europe have published in this field of research and their advances and results are discussed.
CONCLUSIONS: NOTES is a new era in surgery, but it will only partially replace laparoscopy as it will not be suitable for all patients and indications. To make NOTES suitable in daily surgical practice, it will take several years of research. NOTES research will boost the development of new endoscopes and instruments also helping to advance laparoscopic techniques.

Entities:  

Mesh:

Year:  2008        PMID: 18507068

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  2 in total

1.  Laparoendoscopic single site (LESS) cholecystectomy.

Authors:  Steven E Hodgett; Jonathan M Hernandez; Connor A Morton; Sharona B Ross; Michael Albrink; Alexander S Rosemurgy
Journal:  J Gastrointest Surg       Date:  2008-11-22       Impact factor: 3.452

2.  Single-port transumbilical laparoscopic cholecystectomy: A prospective randomised comparison of clinical results of 140 cases.

Authors:  Ramon Vilallonga; Umut Barbaros; Aziz Sümer; Tuğrul Demirel; José Manuel Fort; Oscar González; Nivardo Rodriguez; Manuel Armengol Carrasco
Journal:  J Minim Access Surg       Date:  2012-07       Impact factor: 1.407

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.